Identification of Functional Domains in Kaposica, the Complement Control Protein Homolog of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8)
暂无分享,去创建一个
A. Sahu | Akhilesh K. Singh | Arvind Sahu | Jayati Mullick | Yogesh Panse | Vivekanand Yadav | John Bernet | J. Mullick | V. Yadav | John Bernet | Yogesh Panse | Viveka N Yadav
[1] P. Lachmann. Microbial subversion of the immune response , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Moore,et al. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? , 2003, Annual review of microbiology.
[3] A. Namane,et al. Protein sequencing and identification using tandem mass spectrometry. Edited by Michael Kinter, Nicholas E. Sherman, published by Wiley-Interscience Series on Mass Spectrometry, 2000, 301 p. , 2002 .
[4] E. Cesarman,et al. Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi ’ s Sarcoma – Associated Herpesvirus / Human Herpesvirus - , 1997 .
[5] J. Volanakis. The human complement system in health and disease , 1998 .
[6] M. Pangburn,et al. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. , 1993, The Biochemical journal.
[7] J. Russo,et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] T. Schulz,et al. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). , 1998, The Journal of general virology.
[9] M. Pangburn,et al. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. , 1993, The Biochemical journal.
[10] S. Shchelkunov,et al. Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense , 2000, Journal of Virology.
[11] C. Mold,et al. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. , 1996, Journal of immunology.
[12] D. Lublin,et al. Identification of complement regulatory domains in human factor H. , 1995, Journal of immunology.
[13] D. McCance. Human Tumor Viruses , 1998 .
[14] A. Blom,et al. Structural Requirements for the Complement Regulatory Activities of C4BP* , 2001, The Journal of Biological Chemistry.
[15] A. Blom,et al. Functional Activity of the Complement Regulator Encoded by Kaposi's Sarcoma-associated Herpesvirus* , 2003, The Journal of Biological Chemistry.
[16] B. Levine,et al. Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection. , 2002, Immunity.
[17] Robert B Sim,et al. Interactions between human complement components factor H, factor I and C3b. , 1997, The Biochemical journal.
[18] A. Sahu,et al. Kinetic Analysis of the Interactions between Vaccinia Virus Complement Control Protein and Human Complement Proteins C3b and C4b , 2004, Journal of Virology.
[19] D. Isenman,et al. Identification of Residues within the 727–767 Segment of Human Complement Component C3 Important for Its Interaction with Factor H and with Complement Receptor 1 (CR1, CD35)* , 1999, The Journal of Biological Chemistry.
[20] J. Lambris,et al. Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Open Reading Frame 4 Protein (Kaposica) Is a Functional Homolog of Complement Control Proteins , 2003, Journal of Virology.
[21] A. Alcamí,et al. Viral mechanisms of immune evasion , 2000, Immunology Today.
[22] G. McFadden,et al. Poxviruses and immune evasion. , 2003, Annual review of immunology.
[23] R. Means,et al. Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus. , 2002, Current topics in microbiology and immunology.
[24] B. Moss,et al. Regulation of complement activity by vaccinia virus complement-control protein. , 1992, The Journal of infectious diseases.
[25] H. Ploegh,et al. Virus subversion of immunity: a structural perspective. , 2001, Current opinion in immunology.
[26] D. Hourcade,et al. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. , 2000, Immunopharmacology.
[27] S. Meri,et al. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[28] Therapeutic Interventions in the Complement System , 2000 .
[29] N. Sherman,et al. Protein Sequencing and Identification Using Tandem Mass Spectrometry: Kinter/Tandem Mass Spectrometry , 2000 .
[30] Q. Pan,et al. Two Clusters of Acidic Amino Acids Near the NH2 Terminus of Complement Component C4 α′-Chain Are Important for C2 Binding1 , 2000, The Journal of Immunology.
[31] D. Hourcade,et al. Decay Accelerating Activity of Complement Receptor Type 1 (CD35) , 1999, The Journal of Biological Chemistry.
[32] A. Sahu,et al. Herpes and pox viral complement control proteins: 'the mask of self'. , 2003, Trends in immunology.
[33] O. Spiller,et al. Complement Regulation by Kaposi's Sarcoma-Associated Herpesvirus ORF4 Protein , 2003, Journal of Virology.
[34] N. Cooper. Complement and Viruses , 1998 .
[35] T. Nagashunmugam,et al. Viral interference with antibody and complement , 1998, Seminars in Cell & Developmental Biology.
[36] John D Lambris,et al. Complement Inhibitors Targeting C3, C4, and C5 , 2000 .
[37] B. Morgan. The Human Complement System in Health and Disease. , 1998 .